Generic Supply Chain

AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response

WASHINGTON, DC (January 21, 2020) — The Association for Accessible Medicines (AAM) strongly endorses the Biden administration’s executive orders to strengthen America’s response to the COVID pandemic. Generic medicines have been instrumental in treating COVID patients with severe conditions, serving as a bridge until the COVID vaccines are widely available. AAM’s members are ready to partner with the Biden administration to ensure reliable and predictable access to these vital therapies.

Member Spotlight: Apotex

Based in Toronto, Canada, Apotex also operates in the United States, Mexico and India. The company employs close to 8,000 people worldwide in manufacturing, R&D and commercial operations. Its Apobiologix division focuses on biosimilars development.

Here are some of Apotex’s most recent endeavors with the biggest impact:

Generic and Biosimilar Industry Statement on Essential Medicines Executive Order

WASHINGTON, DC (August 6, 2020) — Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States. The generic industry already makes tens of billions of doses of safe, effective and affordable medicines here in America each year and drafted recommendations to increase that production capacity – “A Blueprint for Enhancing the Security of the U.S.

The Generic and Biosimilar Industry Has a Plan to Secure Our Medicines

The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to "#SecureOurMeds." We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through #COVID and beyond.

Find out more about our path forward:

AAM Statement on Senate Finance Hearing on FDA’s Foreign Manufacturing Inspection Process

WASHINGTON, DC (June 2, 2020) — The COVID-19 crisis exposed many shortcomings in our health care system’s ability to respond to a pandemic. At the same time, many parts of that same system — including the supply chain for the vast majority of generic medicines — demonstrated extraordinary resiliency in the face of unprecedented stresses.

Subscribe to Generic Supply Chain

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.